HPV vaccine approval
This article was originally published in The Gray Sheet
Executive Summary
Introduction of Merck's human papillomavirus vaccine Gardasil will not change the need for Pap or HPV screening, says Digene, which manufacturers the only diagnostic approved by FDA as an adjunct to the Pap test for primary cervical cancer screening. The vaccine is "not a magic bullet for eliminating cervical cancer," Digene says, because it does not protect against all strains of HPV and it is not appropriate for all populations of women. FDA approved the vaccine June 8 for use in girls and women ages 9 to 26. Digene hopes to leverage Merck's vaccine promotions to boost sales of its hc2 High-Risk HPV DNA Test (1"The Gray Sheet" May 15, 2006, p. 12)...
You may also be interested in...
Digene HPV test sales benefit from vaccine approval
Digene human papillomavirus (HPV) test sales of $39.4 mil. in the firm's fiscal fourth quarter (ended June 30) represent a 43% jump from the prior year's fourth quarter, the firm reports Aug. 8. Digene is benefiting from heightened awareness of the benefits of HPV testing due in part to a direct-to-consumer advertising campaign and the June 8 approval of the first HPV vaccine (Merck's Gardasil), Digene says (1"The Gray Sheet" June 12, 2006, In Brief). Corporate revenue advanced 34% in Q4 to $43.3 mil.; for the year, revenue was ahead 33% to $152.9 mil. The firm estimates 18% penetration of a potential U.S. HPV testing market of 35 mil. tests annually. "We believe that our HPV testing business is posed for continued, long-term growth," CEO Evan Jones said...
Digene Looks Forward To Piggybacking On Merck’s HPV Vaccine Ad Campaign
Digene expects a big boost this summer when pharmaceutical giant Merck begins heavily promoting its human papillomavirus (HPV) vaccineGardasil, expected to clear FDA in early June
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.